South Korea’s healthcare landscape has been constantly evolving since the passage of important legislation 20 years ago. However, concern remains about patients’ future ability to obtain access to therapy. The rising costs of therapies has resulted in 20 percent annual growth in the total amount […]
How Did Pharmaceutical Policy Reform Change the Healthcare Landscape in China?
China’s pharmaceutical market is second only to the United States valued at $137 billion (USD). Fueling Growth has been fueled by a number of reforms under the national long-term action plan, “Healthy China 2030.” This plan focuses on patient-centered care and improving access to high-quality […]
Global Experiences: Use of HTA for Health Benefit Packages Development, an ISPOR webinar
Health technology assessment (HTA) is increasingly used to inform universal health coverage (UHC), including financing and priority setting for benefit packages. HEOR and HTA are essential components for informing UHC decision-making. ISPOR is holding a webinar, open to members and non-members, on […]
ISPOR’s CSO Dr. Lucinda Orsini shares views on use of RWE by regulators and HTAs
In this interview with Lucinda Orsini, D.P.M., M.P.H., the Associate Chief Science Officer for the Professional Society for Health Economics and Outcomes Research (ISPOR), she shares her views on navigating the opportunities and challenges of working with RWE. Dr. Orsini sees substantial […]
5 Questions for the New Chair of NICE Sharmila Nebhrajani
S. Nebharajani assumed the role of chair of NICE in May 2020, most recently serving as CEO of Wilton Park, leading the Global Health program looking at issues of AI and data for health systems in Africa, Asia, among other responsibilities. Medscape UK sat down for an interview, exploring […]
PRMA’s Chadwick Highlights Common Omissions in Global Value Dossiers
PRMA Consulting HTA Manager Claire Chadwick in a recent blog post discusses five common omissions in global value dossiers. Chadwick says the following five omissions lead to less robust dossiers: Inadequate justification Insufficient trial and analysis information Poor consideration […]
ISPOR Offering Short Courses on Value Assessment Frameworks, HTA
The International Society of Pharmacoeconomics and Outcomes Research (ISPOR) is offering two short, online courses. Below are the two courses: A Health Economics Approach to US Value Assessment Frameworks, 10 a.m. EST June 23 Introduction to Health Technology Assessment, 10 a.m. EST June […]
New Definition of HTA
In a letter to the editor published in Value in Health, Brian O'Rourke, Wija Oortwijn and Tara Schuller offer a new definition of health technology assessment (HTA). The authors define HTA as the following: "HTA is a multidisciplinary process that uses explicit methods to determine the value […]
Article Considers COVID-19’s Impact on HTA
A recent article by Paula Lorgelly and Amanda Adler looks at how the COVID-19 pandemic is impacting health technology assessment. COVID-19 will have a lasting impact on life as we know it, they write, and it's "likely that HTA will similarly adapt to this shock." "Our healthcare systems are […]
How Can New Software Bolster HTA?
Panelists in an on-demand webinar discuss how new software can be utilized to improve health technology assessment. "The limits of current software are being stretched to breaking points and advanced software have the potential to revolutionize the conduct of complex health technology […]
